Risk of endometrial cancer after tamoxifen treatment of breast cancer
- 19 February 1994
- journal article
- Published by Elsevier in The Lancet
- Vol. 343 (8895), 448-452
- https://doi.org/10.1016/s0140-6736(94)92692-1
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Carcinogenic Effects of Adjuvant Tamoxifen Treatment and Radiotherapy for Early Breast CancerActa Oncologica, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Potential Role of Tamoxifen in Prevention of Breast CancerJNCI Journal of the National Cancer Institute, 1991
- New Perspective on Cancer of the Contralateral Breast: A Marker for Assessing Tamoxifen as a Preventive AgentJNCI Journal of the National Cancer Institute, 1991
- Incidence of New Primary Cancers After Adjuvant Tamoxifen Therapy and Radiotherapy for Early Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Tamoxifen in premenopausal patients with metastatic breast cancer: a review.Journal of Clinical Oncology, 1991
- Prevention of breast cancer with tamoxifen—an update on the royal Marsden Hospital pilot programmeEuropean Journal of Cancer and Clinical Oncology, 1990
- ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERSThe Lancet, 1989
- Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancerBritish Journal of Cancer, 1988
- EVALUATION OF SCREENING FOR BREAST CANCER IN A NON-RANDOMISED STUDY (THE DOM PROJECT) BY MEANS OF A CASE-CONTROL STUDYThe Lancet, 1984